Clinical Aspects and Management of Levodopa-Induced Dyskinesia

Table 2

Adjuvant therapy versus placebo.

	Pramipexole	Ropinirole	Pergolide^*	Bromocriptine	Cabergoline
Off-time reduction (h/day)	−1.81	−0.93	−1.60	−1.78	−1.29
LEDD red (mg/day)	−114.82	−119.81	−183.90	−52.17	−149.60
UPDRS ADL reduction (pts)					−1.78
UPDRS III reduction (pts)		−4.80			−1.74
Incidence of dyskinesia (OR)	2.63	3.21	4.64	2.52	1.44

^*Based on data from just one trial [71].